Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-006)

This study has been completed.
Sponsor:
Information provided by:
Sirion Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT00549289
First received: October 24, 2007
Last updated: NA
Last verified: October 2007
History: No changes posted

October 24, 2007
October 24, 2007
Not Provided
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-006)
Not Provided

The purpose of this phase III, open-label study is to determine the safety and tolerability of cyclosporine in the treatment of dry eye syndrome.

Not Provided
Interventional
Phase 3
Intervention Model: Single Group Assignment
Masking: Open Label
Dry Eye Syndromes
Drug: cyclosporine A
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • Diagnosis of dry eye syndrome

Exclusion Criteria:

  • Intraocular or refractive surgery in the study eye within 3 months prior to study start
  • Unwilling to discontinue use of contact lenses during the study
  • Pregnancy or lactation
Both
2 Years and older
Not Provided
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00549289
ST-603-006
Not Provided
Not Provided
Sirion Therapeutics, Inc.
Not Provided
Study Chair: Roger Vogel Sirion Therapeutics
Sirion Therapeutics, Inc.
October 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP